// App-Quantinova.ai

111 : Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial.

Researchers

Presenter

  • Christopher Williams

Principal Investigators

  • Jenny F. Seligmann

  • Christoph Guetter

  • Liping Zhang

  • Dongyao Yan

  • Andrea Muranyi

  • Isaac Bai

  • Shalini Singh

  • Faye Elliott

  • Mike Shires

  • Susan Richman

  • Nicholas West

  • Jenny Barrett

  • Matthew T. Seymour

  • Philip Quirke

  • Kandavel Shanmugam

Medical Centers

  • Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom

  • Roche Diagnostics, Tucson, AZ

  • Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Amphiregulin

Drug/Treatment

  • amphiregulin

  • panitumumab

  • Irinotecan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT00389870

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved